Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.98
SGYP's Cash to Debt is ranked higher than
63% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.07 vs. SGYP: 0.98 )
SGYP' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 0.98

F-Score: 3
Z-Score: -1.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -280.91
SGYP's ROE (%) is ranked lower than
58% of the 1133 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. SGYP: -280.91 )
SGYP' s 10-Year ROE (%) Range
Min: -899.32   Max: -154.96
Current: -280.91

-899.32
-154.96
ROA (%) -104.67
SGYP's ROA (%) is ranked lower than
58% of the 1166 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. SGYP: -104.67 )
SGYP' s 10-Year ROA (%) Range
Min: -6858.53   Max: -66.95
Current: -104.67

-6858.53
-66.95
ROC (Joel Greenblatt) (%) -15629.64
SGYP's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.41 vs. SGYP: -15629.64 )
SGYP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -423053.33   Max: -532.74
Current: -15629.64

-423053.33
-532.74
EBITDA Growth (3Y)(%) 33.10
SGYP's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 840 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. SGYP: 33.10 )
SGYP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 122.4
Current: 33.1

0
122.4
EPS Growth (3Y)(%) 50.40
SGYP's EPS Growth (3Y)(%) is ranked higher than
96% of the 818 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. SGYP: 50.40 )
SGYP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 122.4
Current: 50.4

0
122.4
» SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SGYP Guru Trades in Q4 2013

Jim Simons 208,600 sh (New)
» More
Q1 2014

SGYP Guru Trades in Q1 2014

Jim Simons 197,390 sh (-5.37%)
» More
Q2 2014

SGYP Guru Trades in Q2 2014

Paul Singer 450,400 sh (unchged)
Jim Simons Sold Out
» More
Q4 2014

SGYP Guru Trades in Q4 2014

Jim Simons 162,095 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -4.51
SGYP's EV-to-EBIT is ranked higher than
60% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.34 vs. SGYP: -4.51 )
SGYP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.51

Current Ratio 10.92
SGYP's Current Ratio is ranked higher than
95% of the 1025 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.23 vs. SGYP: 10.92 )
SGYP' s 10-Year Current Ratio Range
Min: 0.13   Max: 10.92
Current: 10.92

0.13
10.92
Quick Ratio 10.92
SGYP's Quick Ratio is ranked higher than
96% of the 1025 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SGYP: 10.92 )
SGYP' s 10-Year Quick Ratio Range
Min: 0.13   Max: 10.92
Current: 10.92

0.13
10.92

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -22.20
SGYP's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1150 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. SGYP: -22.20 )
SGYP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -36.2   Max: 0
Current: -22.2

-36.2
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S90.Germany,
Synergy Pharmaceuticals Inc was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Synergy Pharma exploring sale - Bloomberg Mar 26 2015
Synergy Pharmaceuticals Said to Weigh Options Including Sale Mar 26 2015
SYNERGY PHARMACEUTICALS, INC. Financials Mar 21 2015
Synergy Pharmaceuticals Reports 2014 Fourth Quarter and Full-Year Financial Results Mar 16 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 16 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 16 2015
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences Feb 03 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 29 2015
Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of... Jan 29 2015
ContraVir to Present at Noble Financial Conference Jan 15 2015
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer Jan 13 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 09 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 08 2015
ContraVir Pharmaceuticals adds Renu Gupta, M.D., to Scientific Advisory Board Jan 08 2015
Synergy Pharmaceuticals Completes Patient Enrollment for the First Pivotal Phase 3 Trial of... Jan 08 2015
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with... Dec 18 2014
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug... Dec 18 2014
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board Dec 16 2014
Synergy Pharmaceuticals Drug Fares Well in Phase II Study Nov 20 2014
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK